Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.

Moyer AM, Suman VJ, Weinshilboum RM, Avula R, Black JL, Safgren SL, Kuffel MJ, Ames MM, Ingle JN, Goetz MP.

Pharmacogenomics. 2011 Nov;12(11):1535-43. doi: 10.2217/pgs.11.97. Epub 2011 Oct 3.

2.

Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.

Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H, Guerrieri-Gonzaga A, Plebani M, Basso D, Gjerde J, Mellgren G, Rotmensz N, Decensi A, Bonanni B.

Pharmacogenomics J. 2011 Apr;11(2):100-7. doi: 10.1038/tpj.2010.17. Epub 2010 Mar 23.

PMID:
20309015
3.

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.

Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM, Lien EA.

Ann Oncol. 2008 Jan;19(1):56-61. Epub 2007 Oct 18.

PMID:
17947222
4.
5.

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H.

J Clin Oncol. 2007 Nov 20;25(33):5187-93.

PMID:
18024866
6.

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.

van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J, Wesseling J, Van 't Veer LJ, Span PN, van Laarhoven H, Sleijfer S, Foekens JA, Linn SC, Berns EM.

Pharmacogenomics. 2011 Aug;12(8):1137-46. doi: 10.2217/pgs.11.54. Epub 2011 Aug 10.

PMID:
21830868
7.

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.

Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S.

Breast Cancer Res. 2007;9(1):R7.

8.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA.

J Natl Cancer Inst. 2005 Jan 5;97(1):30-9.

PMID:
15632378
9.

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.

Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, Ambrosone CB.

Breast Cancer Res Treat. 2005 Jun;91(3):249-58.

10.

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.

Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, Mellgren G, Steen VM, Lien EA.

BMC Cancer. 2010 Jun 21;10:313. doi: 10.1186/1471-2407-10-313.

11.

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.

Wegman P, Vainikka L, Stål O, Nordenskjöld B, Skoog L, Rutqvist LE, Wingren S.

Breast Cancer Res. 2005;7(3):R284-90. Epub 2005 Jan 28.

12.

Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients.

Markiewicz A, Wełnicka-Jaśkiewicz M, Skokowski J, Jaśkiewicz J, Szade J, Jassem J, Zaczek AJ.

PLoS One. 2013 Aug 8;8(8):e72219. doi: 10.1371/journal.pone.0072219. eCollection 2013.

13.

Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.

Sanchez-Spitman AB, Dezentjé VO, Swen JJ, Moes DJAR, Gelderblom H, Guchelaar HJ.

Breast Cancer Res Treat. 2018 Nov;172(2):401-411. doi: 10.1007/s10549-018-4923-7. Epub 2018 Aug 17.

14.

CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.

Ruiter R, Bijl MJ, van Schaik RH, Berns EM, Hofman A, Coebergh JW, van Noord C, Visser LE, Stricker BH.

Pharmacogenomics. 2010 Oct;11(10):1367-75. doi: 10.2217/pgs.10.112.

PMID:
21047200
15.

Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.

Lim JS, Sutiman N, Muerdter TE, Singh O, Cheung YB, Ng RC, Yap YS, Wong NS, Ang PC, Dent R, Schroth W, Schwab M, Chowbay B.

Br J Clin Pharmacol. 2016 Jun;81(6):1142-52. doi: 10.1111/bcp.12886. Epub 2016 Mar 8.

16.

CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.

Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Hauptmann M, van Schaik RH, Berns EM, Vermorken JB, van Diest PJ, Linn SC.

Breast Cancer Res Treat. 2013 Jun;139(3):649-55. doi: 10.1007/s10549-013-2568-0. Epub 2013 Jun 5.

17.

Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy.

Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, Ambrosone CB.

J Natl Cancer Inst. 2002 Nov 6;94(21):1635-40.

PMID:
12419790
18.

Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy.

Grabinski JL, Smith LS, Chisholm GB, Drengler R, Rodriguez GI, Lang AS, Kalter SP, Garner AM, Fichtel LM, Hollsten J, Pollock BH, Kuhn JG.

Breast Cancer Res Treat. 2006 Jan;95(1):13-6.

PMID:
16317586
19.

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN.

J Clin Oncol. 2005 Dec 20;23(36):9312-8.

PMID:
16361630
20.

SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

Tengström M, Mannermaa A, Kosma VM, Hirvonen A, Kataja V.

BMC Cancer. 2012 Jun 18;12:257. doi: 10.1186/1471-2407-12-257.

Supplemental Content

Support Center